To achieve greater effectiveness of therapies in the chronic obstructive pulmonary disease treatment market, manufacturers have integrated combinations of bronchodilators to treat patients with moderate to severe COPD. This includes the combination of long acting beta agonist (LABA) with long acting muscarinic antagonist (LAMA). Thus, the LAMA and LABA group of inhalers are considered safe and effective in COPD patients.
Innovations in Combination Therapy to Dominate COPD Treatment Market
The chronic obstructive pulmonary disease treatment market is projected to be valued at ~US$ 26.2 billion in the year 2027. The high prevalence of chronic obstructive pulmonary disease (COPD) and the need for improved treatment options are catalyzing market growth.
To meet the needs of patients, healthcare companies in the COPD treatment market are developing efficacious treatment options in combination therapy. Revenue of combination therapy was valued at ~US$ 9.6 billion in 2018; the highest amongst all the drug classes in the chronic obstructive pulmonary disease treatment market.
Request the Coronavirus Impact Analysis across Industries and Markets - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=73763
With increased research & development, healthcare companies are innovating new triple combination therapies. For instance, in June 2019, AstraZeneca — an English-Swedish multinational pharmaceutical company, announced the approval of Breztri Aerosphere — a pressurized metered dose inhaler with built-in triple combination therapy for patients suffering from moderate to severe COPD in Japan. Stakeholders in the chronic obstructive pulmonary disease treatment market are running continuous clinical trials to meet the primary endpoints of the disease.
Request a sample to get extensive insights into the Chronic Obstructive Pulmonary Disease (COPD) Treatment Market
Dual and Triple Therapies Minimize Moderate and Severe Exacerbations
With ongoing developments in the chronic obstructive pulmonary disease treatment market, healthcare companies are weighing the responses and combination of therapies in patients. As such, there is a strife between the credibility of dual combination therapy and long acting bronchodilators for treatment in COPD patients.
To achieve greater effectiveness of therapies in the chronic obstructive pulmonary disease treatment market, manufacturers have integrated combinations of bronchodilators to treat patients with moderate to severe COPD. This includes the combination of long acting beta agonist (LABA) with long acting muscarinic antagonist (LAMA). Thus, the LAMA and LABA group of inhalers are considered safe and effective in COPD patients.
Also, triple therapy has shown better outcome in patients as compared to single-agent LAMA monotherapy in the COPD treatment market. Compared with LAMA monotherapy, triple therapy helps to drastically reduce moderate or severe exacerbations. Thus, healthcare companies are making significant improvements to enhance triple therapy against dual therapy LABA/LAMA.
Request For Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=73763
With increased research & development, healthcare companies are innovating new triple combination therapies. For instance, in June 2019, AstraZeneca — an English-Swedish multinational pharmaceutical company, announced the approval of Breztri Aerosphere — a pressurized metered dose inhaler with built-in triple combination therapy for patients suffering from moderate to severe COPD in Japan. Stakeholders in the chronic obstructive pulmonary disease treatment market are running continuous clinical trials to meet the primary endpoints of the disease.
Request a sample to get extensive insights into the Chronic Obstructive Pulmonary Disease (COPD) Treatment Market
Dual and Triple Therapies Minimize Moderate and Severe Exacerbations
With ongoing developments in the chronic obstructive pulmonary disease treatment market, healthcare companies are weighing the responses and combination of therapies in patients. As such, there is a strife between the credibility of dual combination therapy and long acting bronchodilators for treatment in COPD patients.
To achieve greater effectiveness of therapies in the chronic obstructive pulmonary disease treatment market, manufacturers have integrated combinations of bronchodilators to treat patients with moderate to severe COPD. This includes the combination of long acting beta agonist (LABA) with long acting muscarinic antagonist (LAMA). Thus, the LAMA and LABA group of inhalers are considered safe and effective in COPD patients.
Also, triple therapy has shown better outcome in patients as compared to single-agent LAMA monotherapy in the COPD treatment market. Compared with LAMA monotherapy, triple therapy helps to drastically reduce moderate or severe exacerbations. Thus, healthcare companies are making significant improvements to enhance triple therapy against dual therapy LABA/LAMA.
71831